Leslie Andersen

Learn More
BACKGROUND The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease. OBJECTIVE To assess the safety and tolerability of FF/VI over 52 weeks in patients with asthma. METHODS Patients (aged ≥12 years; on inhaled corticosteroid)(More)
BACKGROUND Combination therapy with an inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone. However, there is ongoing debate regarding the risk-benefit ratio of using LABA in asthma. OBJECTIVE To evaluate the effect of the addition of a novel LABA, vilanterol (VI), to a once-daily(More)
BACKGROUND Laboratory studies and a single case-control study have suggested a protective effect of statins on the risk of glioma. We wished to investigate the influence of statin use on the risk of glioma in a population-based setting. METHODS We conducted a nationwide case-control study in Denmark based on population-based medical registries. We(More)
BACKGROUND We assessed the development in the number of new base of tongue squamous-cell carcinoma (BSCC) cases per year in eastern Denmark from 2000 to 2010 and whether HPV may explain any observable increased incidence. METHODS We performed HPV DNA PCR and p16 immunohistochemistry analysis for all (n=210) BSCCs registered in the Danish Head and Neck(More)
tolerability of fluticasone furoate/vilanterol' We thank Dr Lipworth for his response to our article on the safety and tolerability of fluticasone furoate/vilanterol (FF/VI) combination in asthma, 1 in which he specifically discusses effects on urinary cor-tisol. We acknowledge the limitations of urinary cortisol assessment; however, as outlined in the(More)
  • 1